Results showed that CPH:SA‐based IL‐1α‐MPs generated a slow and sustained systemic release of IL‐1α resulting in reduced toxicity (weight loss, cytokine storm, and hypotension) compared to free IL‐1α in tumor‐bearing mice. This evidence concerns the gene IL1A and neoplasm.